LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 43

Search options

  1. Article: Nicotinaldehyde, a Novel Precursor of NAD Biosynthesis, Abrogates the Anti-Cancer Activity of an NAD-Lowering Agent in Leukemia.

    Matsumoto, Saki / Biniecka, Paulina / Bellotti, Axel / Duchosal, Michel A / Nahimana, Aimable

    Cancers

    2023  Volume 15, Issue 3

    Abstract: Targeting NAD depletion in cancer cells has emerged as an attractive therapeutic strategy for cancer treatment, based on the higher reliance of malignant vs. healthy cells on NAD to sustain their aberrant proliferation and altered metabolism. NAD ... ...

    Abstract Targeting NAD depletion in cancer cells has emerged as an attractive therapeutic strategy for cancer treatment, based on the higher reliance of malignant vs. healthy cells on NAD to sustain their aberrant proliferation and altered metabolism. NAD depletion is exquisitely observed when NAMPT, a key enzyme for the biosynthesis of NAD, is inhibited. Growing evidence suggests that alternative NAD sources present in a tumor environment can bypass NAMPT and render its inhibition ineffective. Here, we report the identification of nicotinaldehyde as a novel precursor that can be used for NAD biosynthesis by human leukemia cells. Nicotinaldehyde supplementation replenishes the intracellular NAD level in leukemia cells treated with NAMPT inhibitor APO866 and prevents APO866-induced oxidative stress, mitochondrial dysfunction and ATP depletion. We show here that NAD biosynthesis from nicotinaldehyde depends on NAPRT and occurs via the Preiss-Handler pathway. The availability of nicotinaldehyde in a tumor environment fully blunts the antitumor activity of APO866 in vitro and in vivo. This is the first study to report the role of nicotinaldehyde in the NAD-targeted anti-cancer treatment, highlighting the importance of the tumor metabolic environment in modulating the efficacy of NAD-lowering cancer therapy.
    Language English
    Publishing date 2023-01-27
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers15030787
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Synthesis and structure-activity relationship of new nicotinamide phosphoribosyltransferase inhibitors with antitumor activity on solid and haematological cancer.

    Fratta, Simone / Biniecka, Paulina / Moreno-Vargas, Antonio J / Carmona, Ana T / Nahimana, Aimable / Duchosal, Michel A / Piacente, Francesco / Bruzzone, Santina / Caffa, Irene / Nencioni, Alessio / Robina, Inmaculada

    European journal of medicinal chemistry

    2023  Volume 250, Page(s) 115170

    Abstract: Cancer cells are highly dependent on Nicotinamide phosphoribosyltransferase (NAMPT) activity for proliferation, therefore NAMPT represents an interesting target for the development of anti-cancer drugs. Several compounds, such as FK866 and CHS828, were ... ...

    Abstract Cancer cells are highly dependent on Nicotinamide phosphoribosyltransferase (NAMPT) activity for proliferation, therefore NAMPT represents an interesting target for the development of anti-cancer drugs. Several compounds, such as FK866 and CHS828, were identified as potent NAMPT inhibitors with strong anti-cancer activity, although none of them reached the late stages of clinical trials. We present herein the preparation of three libraries of new inhibitors containing (pyridin-3-yl)triazole, (pyridin-3-yl)thiourea and (pyridin-3/4-yl)cyanoguanidine as cap/connecting unit and a furyl group at the tail position of the compound. Antiproliferative activity in vitro was evaluated on a panel of solid and haematological cancer cell lines and most of the synthesized compounds showed nanomolar or sub-nanomolar cytotoxic activity in MiaPaCa-2 (pancreatic cancer), ML2 (acute myeloid leukemia), JRKT (acute lymphobalistic leukemia), NMLW (Burkitt lymphoma), RPMI8226 (multiple myeloma) and NB4 (acute myeloid leukemia), with lower IC
    MeSH term(s) Humans ; Nicotinamide Phosphoribosyltransferase/metabolism ; NAD/metabolism ; Cell Line, Tumor ; Cytokines/metabolism ; Antineoplastic Agents/pharmacology ; Leukemia/metabolism ; Structure-Activity Relationship ; Hematologic Neoplasms/drug therapy ; Enzyme Inhibitors/pharmacology
    Chemical Substances Nicotinamide Phosphoribosyltransferase (EC 2.4.2.12) ; NAD (0U46U6E8UK) ; Cytokines ; Antineoplastic Agents ; Enzyme Inhibitors
    Language English
    Publishing date 2023-01-31
    Publishing country France
    Document type Journal Article
    ZDB-ID 188597-2
    ISSN 1768-3254 ; 0009-4374 ; 0223-5234
    ISSN (online) 1768-3254
    ISSN 0009-4374 ; 0223-5234
    DOI 10.1016/j.ejmech.2023.115170
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies.

    Biniecka, Paulina / Matsumoto, Saki / Belotti, Axel / Joussot, Jessie / Bai, Jian Fei / Majjigapu, Somi Reddy / Thoueille, Paul / Spaggiari, Dany / Desfontaine, Vincent / Piacente, Francesco / Bruzzone, Santina / Cea, Michele / Decosterd, Laurent A / Vogel, Pierre / Nencioni, Alessio / Duchosal, Michel A / Nahimana, Aimable

    Molecules (Basel, Switzerland)

    2023  Volume 28, Issue 4

    Abstract: Targeting cancer cells that are highly dependent on the nicotinamide adenine dinucleotide (NAD+) metabolite is a promising therapeutic strategy. Nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme catalyzing ... ...

    Abstract Targeting cancer cells that are highly dependent on the nicotinamide adenine dinucleotide (NAD+) metabolite is a promising therapeutic strategy. Nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme catalyzing NAD
    MeSH term(s) Animals ; Humans ; Mice ; Cell Line, Tumor ; Cytokines/metabolism ; Enzyme Inhibitors/pharmacology ; Hematologic Neoplasms/drug therapy ; NAD/metabolism ; Nicotinamide Phosphoribosyltransferase/antagonists & inhibitors ; Reactive Oxygen Species
    Chemical Substances Cytokines ; Enzyme Inhibitors ; NAD (0U46U6E8UK) ; Nicotinamide Phosphoribosyltransferase (EC 2.4.2.12) ; Reactive Oxygen Species
    Language English
    Publishing date 2023-02-16
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 1413402-0
    ISSN 1420-3049 ; 1431-5165 ; 1420-3049
    ISSN (online) 1420-3049
    ISSN 1431-5165 ; 1420-3049
    DOI 10.3390/molecules28041897
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Gut microbiota severely hampers the efficacy of NAD-lowering therapy in leukemia.

    ElMokh, Oussama / Matsumoto, Saki / Biniecka, Paulina / Bellotti, Axel / Schaeuble, Karin / Piacente, Francesco / Gallart-Ayala, Hector / Ivanisevic, Julijana / Stamenkovic, Ivan / Nencioni, Alessio / Nahimana, Aimable / Duchosal, Michel A

    Cell death & disease

    2022  Volume 13, Issue 4, Page(s) 320

    Abstract: Most cancer cells have high need for nicotinamide adenine dinucleotide ( ... ...

    Abstract Most cancer cells have high need for nicotinamide adenine dinucleotide (NAD
    MeSH term(s) Cell Line, Tumor ; Cytokines/metabolism ; Gastrointestinal Microbiome ; Humans ; Leukemia ; NAD/metabolism ; Neoplasms ; Niacinamide/pharmacology ; Niacinamide/therapeutic use ; Nicotinamide Phosphoribosyltransferase/metabolism
    Chemical Substances Cytokines ; NAD (0U46U6E8UK) ; Niacinamide (25X51I8RD4) ; Nicotinamide Phosphoribosyltransferase (EC 2.4.2.12)
    Language English
    Publishing date 2022-04-08
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2541626-1
    ISSN 2041-4889 ; 2041-4889
    ISSN (online) 2041-4889
    ISSN 2041-4889
    DOI 10.1038/s41419-022-04763-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Activation of Bone Marrow-Derived Cells Angiotensin (Ang) II Type 1 Receptor by Ang II Promotes Atherosclerotic Plaque Vulnerability.

    Pellegrin, Maxime / Bouzourène, Karima / Aubert, Jean-François / Nahimana, Aimable / Duchosal, Michel A / Mazzolai, Lucia

    International journal of molecular sciences

    2018  Volume 19, Issue 9

    Abstract: Angiotensin (Ang) II triggers vulnerable atherosclerotic plaque development. Bone marrow (BM)-derived cells are key players in atherogenesis but whether Ang II induces plaque vulnerability directly through Ang II type 1 receptor (AT1R) activation on ... ...

    Abstract Angiotensin (Ang) II triggers vulnerable atherosclerotic plaque development. Bone marrow (BM)-derived cells are key players in atherogenesis but whether Ang II induces plaque vulnerability directly through Ang II type 1 receptor (AT1R) activation on these cells remains to be clarified. In the present study, we investigated whether a lack of AT1R on BM-derived cells might affect Ang II-mediated vulnerable plaque development. The 2-kidney, 1-clip (2K1C) model (Ang II-dependent mouse model of advanced atherosclerosis and vulnerable plaques) was generated in ApoE
    MeSH term(s) Angiotensins/adverse effects ; Animals ; Apolipoproteins E/genetics ; Bone Marrow Cells/cytology ; Bone Marrow Cells/drug effects ; Bone Marrow Transplantation ; Cytokines/genetics ; Disease Models, Animal ; Gene Expression Regulation/drug effects ; Gene Knockdown Techniques ; Humans ; Lipid Metabolism ; Liver/drug effects ; Liver/metabolism ; Mice ; Plaque, Atherosclerotic/chemically induced ; Plaque, Atherosclerotic/genetics ; Plaque, Atherosclerotic/immunology ; Receptor, Angiotensin, Type 1/genetics
    Chemical Substances Agtr1a protein, mouse ; Angiotensins ; Apolipoproteins E ; Cytokines ; Receptor, Angiotensin, Type 1
    Language English
    Publishing date 2018-09-04
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms19092621
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Identification of NAPRT Inhibitors with Anti-Cancer Properties by In Silico Drug Discovery.

    Ghanem, Moustafa S / Caffa, Irene / Del Rio, Alberto / Franco, Jorge / Parenti, Marco Daniele / Monacelli, Fiammetta / Cea, Michele / Khalifa, Amr / Nahimana, Aimable / Duchosal, Michel A / Ravera, Silvia / Bertola, Nadia / Bruzzone, Santina / Nencioni, Alessio / Piacente, Francesco

    Pharmaceuticals (Basel, Switzerland)

    2022  Volume 15, Issue 7

    Abstract: Depriving cancer cells of sufficient NAD levels, mainly through interfering with their NAD-producing capacity, has been conceived as a promising anti-cancer strategy. Numerous inhibitors of the NAD-producing enzyme, nicotinamide phosphoribosyltransferase ...

    Abstract Depriving cancer cells of sufficient NAD levels, mainly through interfering with their NAD-producing capacity, has been conceived as a promising anti-cancer strategy. Numerous inhibitors of the NAD-producing enzyme, nicotinamide phosphoribosyltransferase (NAMPT), have been developed over the past two decades. However, their limited anti-cancer activity in clinical trials raised the possibility that cancer cells may also exploit alternative NAD-producing enzymes. Recent studies show the relevance of nicotinic acid phosphoribosyltransferase (NAPRT), the rate-limiting enzyme of the Preiss-Handler NAD-production pathway for a large group of human cancers. We demonstrated that the NAPRT inhibitor 2-hydroxynicotinic acid (2-HNA) cooperates with the NAMPT inhibitor FK866 in killing NAPRT-proficient cancer cells that were otherwise insensitive to FK866 alone. Despite this emerging relevance of NAPRT as a potential target in cancer therapy, very few NAPRT inhibitors exist. Starting from a high-throughput virtual screening approach, we were able to identify and annotate two additional chemical scaffolds that function as NAPRT inhibitors. These compounds show comparable anti-cancer activity to 2-HNA and improved predicted aqueous solubility, in addition to demonstrating favorable drug-like profiles.
    Language English
    Publishing date 2022-07-10
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2193542-7
    ISSN 1424-8247
    ISSN 1424-8247
    DOI 10.3390/ph15070848
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Imatinib Uptake into Cells is Not Mediated by Organic Cation Transporters OCT1, OCT2, or OCT3, But is Influenced by Extracellular pH.

    Blanc Mettral, Jaurès / Faller, Nicolas / Cruchon, Sandra / Sottas, Loïc / Buclin, Thierry / Schild, Laurent / Choong, Eva / Nahimana, Aimable / Decosterd, Laurent A

    Drug metabolism letters

    2019  Volume 13, Issue 2, Page(s) 102–110

    Abstract: Background: Cancer cells undergo genetic and environmental changes that can alter cellular disposition of drugs, notably by alterations of transmembrane drug transporters expression. Whether the influx organic cation transporter 1 (OCT1) encoded by the ... ...

    Abstract Background: Cancer cells undergo genetic and environmental changes that can alter cellular disposition of drugs, notably by alterations of transmembrane drug transporters expression. Whether the influx organic cation transporter 1 (OCT1) encoded by the gene SLC221A1 is implicated in the cellular uptake of imatinib is still controversial. Besides, imatinib ionization state may be modulated by the hypoxic acidic surrounding extracellular microenvironment.
    Objective: To determine the functional contribution of OCTs and extracellular pH on imatinib cellular disposition.
    Methods: We measured imatinib uptake in two different models of selective OCTs drug transporter expression (transfected Xenopus laevis oocytes and OCT-expressing HEK293 human cells), incubated at pH 7.4 and 6, using specific mass spectrometry analysis.
    Results: Imatinib cellular uptake occurred independently of OCT1- OCT2- or OCT3-mediated drug transport at pH 7.4. Uptake of the OCTs substrate tetraethylammonium in oocytes remained intact at pH 6, while the accumulation of imatinib in oocytes was 10-fold lower than at pH 7.4, irrespectively of OCTs expressions. In OCT1- and OCT2-HEK cells at pH 6, imatinib accumulation was reduced by 2- 3-fold regardless of OCTs expressions. Since 99.5% of imatinib at pH6 is under the cationic form, the reduced cellular accumulation of imatinib at such pH may be explained by the lower amount of uncharged imatinib remaining for passive diffusion across cellular membrane.
    Conclusion: Imatinib is not a substrate of OCTs 1-3 while the environmental pH modulates cellular disposition of imatinib. The observation that a slightly acidic extracellular pH influences imatinib cellular accumulation is important, considering the low extracellular pH reported in the hematopoietic leukemia/ cancer cell microenvironment.
    MeSH term(s) Animals ; Extracellular Space/chemistry ; HEK293 Cells ; Humans ; Hydrogen-Ion Concentration ; Imatinib Mesylate/pharmacokinetics ; Imatinib Mesylate/therapeutic use ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology ; Octamer Transcription Factor-1/metabolism ; Oocytes ; Organic Cation Transport Proteins/metabolism ; Organic Cation Transporter 2/metabolism ; Protein Kinase Inhibitors/pharmacokinetics ; Protein Kinase Inhibitors/therapeutic use ; Xenopus laevis
    Chemical Substances Octamer Transcription Factor-1 ; Organic Cation Transport Proteins ; Organic Cation Transporter 2 ; POU2F1 protein, human ; Protein Kinase Inhibitors ; SLC22A2 protein, human ; solute carrier family 22 (organic cation transporter), member 3 ; Imatinib Mesylate (8A1O1M485B)
    Language English
    Publishing date 2019-02-08
    Publishing country United Arab Emirates
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 1874-0758
    ISSN (online) 1874-0758
    DOI 10.2174/1872312813666190207150207
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Identification of new FK866 analogues with potent anticancer activity against pancreatic cancer.

    Bai, Jian-Fei / Majjigapu, Somi Reddy / Sordat, Bernard / Poty, Sophie / Vogel, Pierre / Elías-Rodríguez, Pilar / Moreno-Vargas, Antonio J / Carmona, Ana T / Caffa, Irene / Ghanem, Moustafa / Khalifa, Amr / Monacelli, Fiammetta / Cea, Michele / Robina, Inmaculada / Gajate, Consuelo / Mollinedo, Faustino / Bellotti, Axel / Nahimana, Aimable / Duchosal, Michel /
    Nencioni, Alessio

    European journal of medicinal chemistry

    2022  Volume 239, Page(s) 114504

    Abstract: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal diseases for which chemotherapy has not been very successful yet. FK866 ((E)-N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide) is a well-known NAMPT (nicotinamide ... ...

    Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal diseases for which chemotherapy has not been very successful yet. FK866 ((E)-N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide) is a well-known NAMPT (nicotinamide phosphoribosyltransferase) inhibitor with anti-cancer activities, but it failed in phase II clinical trials. We found that FK866 shows anti-proliferative activity in three PDAC cell lines, as well as in Jurkat T-cell leukemia cells. More than 50 FK866 analogues were synthesized that introduce substituents on the phenyl ring of the piperidine benzamide group of FK866 and exchange its buta-1,4-diyl tether for 1-oxyprop-3-yl, (E)-but-2-en-1,4-diyl and 2- and 3-carbon tethers. The pyridin-3-yl moiety of FK866 was exchanged for chlorinated and fluorinated analogues and for pyrazin-2-yl and pyridazin-4-yl groups. Several compounds showed low nanomolar or sub-nanomolar cell growth inhibitory activity. Our best cell anti-proliferative compounds were the 2,4,6-trimethoxybenzamide analogue of FK866 ((E)-N-(4-(1-(2,4,6-trimethoxybenzoyl)piperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide) (9), the 2,6-dimethoxybenzamide (8) and 2-methoxybenzamide (4), which exhibited an IC
    MeSH term(s) Acrylamides/chemistry ; Acrylamides/pharmacology ; Antineoplastic Agents/pharmacology ; Carcinoma, Pancreatic Ductal/drug therapy ; Cytokines ; Humans ; Pancreatic Neoplasms/drug therapy ; Piperidines/chemistry ; Piperidines/pharmacology ; Pancreatic Neoplasms
    Chemical Substances Acrylamides ; Antineoplastic Agents ; Cytokines ; N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide ; Piperidines
    Language English
    Publishing date 2022-06-02
    Publishing country France
    Document type Journal Article
    ZDB-ID 188597-2
    ISSN 1768-3254 ; 0009-4374 ; 0223-5234
    ISSN (online) 1768-3254
    ISSN 0009-4374 ; 0223-5234
    DOI 10.1016/j.ejmech.2022.114504
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Reactive oxygen/nitrogen species contribute substantially to the antileukemia effect of APO866, a NAD lowering agent.

    Cloux, Anne-Julie / Aubry, Dominique / Heulot, Mathieu / Widmann, Christian / ElMokh, Oussama / Piacente, Francesco / Cea, Michele / Nencioni, Alessio / Bellotti, Axel / Bouzourène, Karima / Pellegrin, Maxime / Mazzolai, Lucia / Duchosal, Michel A / Nahimana, Aimable

    Oncotarget

    2019  Volume 10, Issue 62, Page(s) 6723–6738

    Abstract: APO866 is a small molecule drug that specifically inhibits nicotinamide phosphoribosyltransferase (NAMPT), a key enzyme involved in nicotinamide adenine dinucleotide (NAD) biosynthesis from the natural precursor nicotinamide. Although, the antitumor ... ...

    Abstract APO866 is a small molecule drug that specifically inhibits nicotinamide phosphoribosyltransferase (NAMPT), a key enzyme involved in nicotinamide adenine dinucleotide (NAD) biosynthesis from the natural precursor nicotinamide. Although, the antitumor activity of APO866 on various types of cancer models has been reported, information regarding mechanisms by which APO866 exerts its cytotoxic effects is not well defined. Here we show that APO866 induces a strong, time-dependent increase in highly reactive ROS, nitric oxide, cytosolic/mitochondrial superoxide anions and hydrogen peroxide. We provide evidence that APO866-mediated ROS production is modulated by PARP1 and triggers cell death through mitochondria depolarization and ATP loss. Genetic or pharmacologic inhibition of PARP1 prevented hydrogen peroxide accumulation, caspase activation, mitochondria depolarization, ATP loss and abrogates APO866-induced cell death, suggesting that the integrity of PARP1 status is required for cell death. Conversely, PARP1 activating drugs enhanced the anti-leukemia activity of APO866 Collectively, our studies show that APO866 induces ROS/RNS productions, which mediate its anti-leukemia effect. These results support testing new combinatorial strategies to enhance the antitumor activities of APO866.
    Language English
    Publishing date 2019-11-19
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2560162-3
    ISSN 1949-2553 ; 1949-2553
    ISSN (online) 1949-2553
    ISSN 1949-2553
    DOI 10.18632/oncotarget.27336
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: The TAT-RasGAP317-326 anti-cancer peptide can kill in a caspase-, apoptosis-, and necroptosis-independent manner.

    Heulot, Mathieu / Chevalier, Nadja / Puyal, Julien / Margue, Christiane / Michel, Sébastien / Kreis, Stephanie / Kulms, Dagmar / Barras, David / Nahimana, Aimable / Widmann, Christian

    Oncotarget

    2016  Volume 7, Issue 39, Page(s) 64342–64359

    Abstract: Tumor cell resistance to apoptosis, which is triggered by many anti-tumor therapies, remains a major clinical problem. Therefore, development of more efficient therapies is a priority to improve cancer prognosis. We have previously shown that a cell- ... ...

    Abstract Tumor cell resistance to apoptosis, which is triggered by many anti-tumor therapies, remains a major clinical problem. Therefore, development of more efficient therapies is a priority to improve cancer prognosis. We have previously shown that a cell-permeable peptide derived from the p120 Ras GTPase-activating protein (RasGAP), called TAT-RasGAP317-326, bears anti-malignant activities in vitro and in vivo, such as inhibition of metastatic progression and tumor cell sensitization to cell death induced by various anti-cancer treatments. Recently, we discovered that this RasGAP-derived peptide possesses the ability to directly kill some cancer cells. TAT-RasGAP317-326 can cause cell death in a manner that can be either partially caspase-dependent or fully caspase-independent. Indeed, TAT-RasGAP317-326-induced toxicity was not or only partially prevented when apoptosis was inhibited. Moreover, blocking other forms of cell death, such as necroptosis, parthanatos, pyroptosis and autophagy did not hamper the killing activity of the peptide. The death induced by TAT-RasGAP317-326 can therefore proceed independently from these modes of death. Our finding has potentially interesting clinical relevance because activation of a death pathway that is distinct from apoptosis and necroptosis in tumor cells could lead to the generation of anti-cancer drugs that target pathways not yet considered for cancer treatment.
    Language English
    Publishing date 2016-09-27
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2560162-3
    ISSN 1949-2553 ; 1949-2553
    ISSN (online) 1949-2553
    ISSN 1949-2553
    DOI 10.18632/oncotarget.11841
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top